Arrowhead Pharmaceuticals Stock Today
| ARWR Stock | USD 19.95 0.08 0.40% |
Performance2 of 100
| Odds Of DistressOver 53
|
Arrowhead Pharmaceuticals is selling at 19.95 as of the 29th of January 2025; that is 0.4 percent decrease since the beginning of the trading day. The stock's lowest day price was 19.69. Arrowhead Pharmaceuticals has 53 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 1st of October 2024 and ending today, the 29th of January 2025. Click here to learn more.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Arrowhead Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 124.43 M outstanding shares of which 9.66 M shares are presently shorted by private and institutional investors with about 8.94 trading days to cover. More on Arrowhead Pharmaceuticals
Arrowhead Stock Highlights
Arrowhead Pharmaceuticals (ARWR) is traded on NASDAQ Exchange in USA. It is located in 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 and employs 525 people. Arrowhead Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.49 B. Arrowhead Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 124.43 M outstanding shares of which 9.66 M shares are presently shorted by private and institutional investors with about 8.94 trading days to cover.
Arrowhead Pharmaceuticals currently holds about 416.5 M in cash with (462.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.93.
Check Arrowhead Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationArrowhead Pharmaceuticals holds a total of 124.43 Million outstanding shares. The majority of Arrowhead Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arrowhead Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arrowhead Pharmaceuticals. Please pay attention to any change in the institutional holdings of Arrowhead Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Arrowhead Ownership Details
Arrowhead Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Arrowhead Pharmaceuticals market risk premium is the additional return an investor will receive from holding Arrowhead Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0386 | |||
| Jensen Alpha | 0.0853 | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0222 |
Arrowhead Stock Against Markets
Arrowhead Pharmaceuticals Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Kenneth Myszkowski | Chief Officer | Profile | |
| Javier MD | Chief Officer | Profile | |
| Bruce MD | Chief Scientist | Profile | |
| Vincent CFA | Head VP | Profile | |
| MBA MD | Chief Medicine | Profile | |
| Tracie Oliver | Chief Officer | Profile |
Already Invested in Arrowhead Pharmaceuticals?
The danger of trading Arrowhead Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arrowhead Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arrowhead Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arrowhead Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.